New pill targets rare Cancer's genetic driver
Disease control
Recruiting now
This early-stage study is testing a new oral medication called REM-422 for people with advanced adenoid cystic carcinoma (ACC), a rare cancer. The main goals are to find a safe and effective dose and to see if the drug can shrink or control tumors. The study will enroll about 100…
Phase: PHASE1, PHASE2 • Sponsor: Remix Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC